久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

美國RayBiotech
RayBiotech,Inc. 目前正致力于為后基因時代開發創新，可靠的技術，在完成人類基因組序列之后，研究人員已經能夠分析表達無數與疾病有關的基因。并且他們已經率先開發出高品質的抗體和能夠同時有效地分析數百種有關炎癥，血管生成，細胞凋亡，細胞生長和從一個單一的生物樣品信號轉導的蛋白表達結果的蛋白質陣列技術。
產品簡介如下：
Cytokine Antibody Array
Quantitative Antibody Array
Apoptosis Array
Phosphorylation Antibody Array
Enzyme Immunoassay (EIA) Based Kits
Protein Array
RayBio® ELISA kit
L Series: Label-Based Antibody Array
Tissue Microarray
Phosphorylation ELISA kit
Peptide & Peptide Synthesis

At RayBiotech, we are committed to developing innovative and reliable technologies for the post-genomic age. Our mission is to provide cutting edge proteomics tools for the advancement of basic and clinical research, the development of better patient diagnostics, and the facilitation of drug and biomarker discovery. It is also our mission to provide excellent service and support to our valued customers.

?

Following the completion of the human genome sequence, researchers have been able to analyze the expression of a myriad of disease-related genes. However, since many diseases result from abnormal protein expression, post-translational modifications, or interactions with other biomolecules, an understanding of disease states cannot be obtained from genomic research alone. It is our realization that high-throughput and efficient protein analysis offers the most promising approach for discovering novel drug targets, disease biomarkers and therapeutic agents.

At RayBiotech, we have pioneered the development of high quality antibody and protein array technology to efficiently analyze the concurrent expression and function of hundreds of proteins involved in inflammation, angiogenesis, apoptosis, cell growth, and signal transduction from a single biological sample. Thus, RayBiotech provides a reliable high-throughput technology for screening of novel biomarkers, identification of new drug targets, determination of key factors, as well as for accurate, early detection of diseases. Our technologies have the potential to contribute significantly to the realization of the heralded promise of personalized medicine for patients.
?